Overview
Start/End Dates
Locations
Djavad Mowafaghian Centre for Brain Health
UBC Hospital
Name/Title
Christopher Mok, Research Coordinator
Phone
Email Address
Purpose of Study
In people with amyotrophic lateral sclerosis (ALS), faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.
The study consists of back-to-back treatment phases, with an optional extension phase. In the initial phase, participants will randomly receive the study drug, a placebo or a mixed regimen of both. In the extension phase, participants will randomly receive the study drug or a mixed regimen. Participants will complete up to 15 in-person visits across both phases, involving drug administration, blood collection, clinical assessments and procedures. There will be phone calls between visits to monitor participant safety and drug self-administration compliance.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
In people with amyotrophic lateral sclerosis (ALS), faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.
The study consists of back-to-back treatment phases, with an optional extension phase. In the initial phase, participants will randomly receive the study drug, a placebo or a mixed regimen of both. In the extension phase, participants will randomly receive the study drug or a mixed regimen. Participants will complete up to 15 in-person visits across both phases, involving drug administration, blood collection, clinical assessments and procedures. There will be phone calls between visits to monitor participant safety and drug self-administration compliance.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
